Private equity operating partners in life sciences sit at a distinctive intersection of pharmaceutical expertise, investment acumen, and executive leadership that makes the role one of the most complex to benchmark in the senior compensation landscape. Unlike generalist PE operating partners who might oversee portfolio companies across consumer, industrial, and technology sectors, life sciences PE operating partners require deep domain knowledge in drug development, medical device commercialization, regulatory strategy, or healthcare services operations — combined with the financial literacy and investor-relationship skills that the PE model demands.
The compensation range reflects this complexity. In our 2023–2025 life sciences PE operating partner placement data, total annual compensation ranged from $384K to over $3M, with the variance driven primarily by fund size, portfolio scope, and whether the operating partner participates in carried interest on the fund’s life sciences investments. This piece breaks down the components of that range, explains the portfolio company oversight models that shape the role, and provides practical guidance for executives evaluating life sciences PE opportunities.
The compensation structure
Life sciences PE operating partner compensation consists of four distinct components that must be analyzed separately:
Base retainer or salary. The guaranteed cash component at life sciences-focused PE firms runs $280K to $550K annually, depending on fund size and the operating partner’s seniority. At healthcare-focused mid-market funds ($500M to $3B), the typical range is $320K to $480K. At larger funds with dedicated life sciences platforms (e.g., the healthcare arms of Blackstone, KKR, Warburg Pincus), retainers can reach $500K to $650K. The retainer is notably higher than at generalist PE firms for equivalent seniority levels, reflecting the specialized expertise required and the smaller pool of qualified candidates.
Portfolio company compensation. When a life sciences PE operating partner serves in an interim executive capacity at a portfolio company — as acting CEO during a leadership transition, as interim Chief Commercial Officer during a product launch, or as temporary head of manufacturing during a facility build-out — they typically receive additional compensation from the portfolio company. In life sciences PE, these engagements are more common and more intensive than in generalist PE, because the technical complexity of pharmaceutical and medical device operations often requires hands-on operating leadership rather than advisory oversight. Interim executive compensation at life sciences portfolio companies runs $200K to $500K annually, depending on engagement intensity.
Carried interest. The most consequential and most variable component. Life sciences-focused PE funds typically allocate carried interest to operating partners who contribute meaningfully to portfolio company value creation. A 0.3% to 1.0% carry allocation in a successful $2B healthcare fund that generates a 2.5x net return can produce $2M to $7M in carry distributions over the fund’s life. The distributions occur at exit, not during the hold period, and are subject to clawback provisions if the fund underperforms on subsequent investments. The life sciences-specific nuance is that portfolio company exits in pharma and medtech are often M&A transactions (acquisition by a larger pharma company) rather than IPOs, which means exit timing and valuation are driven by acquirer interest and strategic fit rather than public market conditions.
Co-investment rights. Life sciences PE firms regularly offer operating partners the opportunity to co-invest personal capital in specific portfolio company transactions. For operating partners with the capital and conviction, co-investment provides direct equity exposure to portfolio companies at the same terms as the fund. The sums involved can be significant: co-investment opportunities of $250K to $2M per transaction are common at mid-market and large healthcare PE funds. The alignment of interests this creates is particularly valuable in life sciences, where the operating partner’s domain expertise directly influences the investment thesis and operating plan.
Carried interest in life sciences PE
Carry in life sciences PE operates under the same general framework as carry in any PE fund, but the value creation mechanics are specific to the healthcare sector and have direct implications for operating partner compensation.
In pharma and biotech PE, portfolio company value is often created through clinical development milestones (advancing a drug candidate through Phase 2 to Phase 3, obtaining regulatory approval) and commercial execution (launching a product, building market share, expanding into new indications or geographies). Operating partners who have direct expertise in these value-creation activities — a former CMO who can oversee clinical development strategy, or a former CCO who can build a commercial organization from scratch — are more directly connected to the investment thesis than generalist operating partners, which justifies larger carry allocations.
In medtech PE, value creation is often driven by manufacturing scale-up (transitioning from pilot production to commercial-scale manufacturing), regulatory clearance (obtaining 510(k) or PMA approval for new products), and commercial channel development (building relationships with hospital systems, GPOs, and distributors). Operating partners with specific medtech operations experience contribute directly to these value drivers in ways that generalist PE operating experience cannot replicate.
The practical implication for carry allocation: life sciences PE operating partners with specific, relevant domain expertise typically receive 20% to 40% larger carry allocations than generalist operating partners at comparable fund sizes, reflecting the more direct connection between their expertise and the fund’s value creation thesis.
Portfolio company oversight models
Life sciences PE firms deploy operating partners in three primary models, and the model determines both the day-to-day work and the compensation structure:
Board-level advisory. The operating partner sits on portfolio company boards, reviews quarterly performance, provides strategic input on clinical development or commercial strategy, and connects portfolio companies to resources in the PE firm’s network. This is the lightest-touch model: the operating partner may oversee 8 to 12 portfolio companies simultaneously, spending 1 to 2 days per month on each. Compensation is primarily fund retainer plus carry, with limited portfolio company direct compensation.
Active operational involvement. The operating partner works directly with portfolio company management teams on specific operational initiatives: building out a commercial organization, redesigning manufacturing processes, restructuring regulatory strategy, or managing a clinical program transition. Engagement intensity is higher (2 to 4 days per week at each active company), and the operating partner may be actively involved with 3 to 5 companies at any time. Compensation includes both fund retainer and significant portfolio company compensation.
Interim executive deployment. The operating partner serves as a full-time executive at a specific portfolio company for a defined period, typically 6 to 18 months. This model is used when a portfolio company faces a leadership vacuum (CEO departure, CMO exit), a critical operational challenge (FDA warning letter, commercial launch execution), or a pre-sale preparation that requires experienced executive leadership to maximize exit valuation. Compensation during interim deployment is the highest of the three models, combining fund retainer, portfolio company executive compensation, and often enhanced carry or co-investment terms specific to the engagement.
Value creation plans specific to pharma/medtech
The value creation plan (VCP) is the operational blueprint that PE firms develop for each portfolio company acquisition, and life sciences VCPs have specific characteristics that differentiate them from VCPs in other sectors.
In pharma portfolio companies, VCPs typically focus on: pipeline prioritization (which development programs to advance, partner, or terminate), regulatory strategy optimization (identifying the fastest path to approval with the highest probability of success), commercial launch preparation (building market access, medical affairs, and field force capabilities), and manufacturing efficiency (reducing COGS through process optimization or site consolidation). Operating partners with CMO, VP R&D, or CCO backgrounds are directly responsible for executing these VCP elements.
In medtech portfolio companies, VCPs focus on: product portfolio rationalization, manufacturing scale-up and cost reduction, regulatory pathway management for new products, and commercial channel expansion through hospital system and GPO relationships. Operating partners with medtech commercial or manufacturing backgrounds drive these initiatives.
The operating partner’s contribution to VCP execution is the primary determinant of their long-term compensation through carry. A successful VCP execution that drives a portfolio company from $200M to $500M in enterprise value creates significant carry value for operating partners with meaningful allocations. An unsuccessful VCP — a failed clinical trial, a regulatory setback, or a commercial launch that underperforms — may reduce or eliminate carry value for that specific investment.
Comp by fund size and stage
The relationship between fund size and life sciences PE operating partner compensation is direct and predictable:
Funds below $500M (growth equity, small buyout): retainer $200K to $350K; carry allocation typically 0.1% to 0.3%; total annual realization $384K to $700K in a reasonable vintage. These funds often require operating partners to take more hands-on interim executive roles because they cannot afford to hire permanent C-suite talent for smaller portfolio companies.
Funds $500M to $2B (mid-market buyout): retainer $350K to $550K; carry allocation 0.3% to 0.8%; total annual realization $600K to $1.8M. This is the segment where life sciences PE operating partners have the most direct impact on portfolio company outcomes and where the carry-to-retainer ratio is most favorable.
Funds above $2B (large buyout, healthcare platform): retainer $480K to $700K; carry allocation 0.5% to 1.5%; total annual realization can exceed $1.5M to $3M+ in strong vintages. At this level, operating partners are typically former C-suite executives from large pharma or medtech companies who bring institutional credibility and deal-sourcing relationships alongside operational expertise.
How to evaluate life sciences PE opportunities
For executives considering life sciences PE operating partner roles, the single most important due diligence question is the same as for generalist PE: what is the fund’s track record with operating partners, specifically? How long do operating partners stay? What has happened to their predecessors? What carry distributions have they actually received?
Beyond that fundamental question, life sciences PE opportunities require three additional evaluation criteria:
Therapeutic and sector alignment. An operating partner whose expertise is in oncology drug development will be less effective — and less well-compensated through carry — at a fund whose portfolio is concentrated in medical devices or healthcare services. Evaluate the fund’s investment thesis and portfolio composition against your specific domain expertise. The best life sciences PE placements we see are those where the operating partner’s clinical or commercial background maps directly onto the fund’s current portfolio and anticipated deal pipeline.
The deal team’s respect for operating expertise. At the best life sciences PE firms, operating partners participate meaningfully in deal selection and due diligence, not just post-acquisition operational improvement. They are consulted on clinical feasibility, regulatory risk, and commercial potential before the deal closes, not just asked to execute a plan that was developed without their input. At weaker firms, operating partners are treated as support staff who execute someone else’s VCP. The organizational culture around operating partners directly affects both the quality of the work and the carry allocation that results from it.
Exit horizon and portfolio maturity. Carry distributions depend on exits, and the timing of exits in life sciences PE can be long and uncertain. A fund that is currently in its investment period (deploying capital into new portfolio companies) may be 5 to 8 years away from significant carry distributions. An operating partner joining at this stage is making a long-duration commitment. A fund that is in its value-creation period (holding and operating portfolio companies acquired in an earlier vintage) may be closer to exits, but the carry allocation for a new operating partner may be smaller because the value creation is already partially accomplished.
For current data on life sciences executive compensation across all employer types, see our 2026 Life Sciences Executive Compensation Report.
This piece is authored by Catherine Harrington (Talent Partner) with contributions from Malcolm Sheffield on life sciences PE placement data and the Alden Search research team.